ESLA Estrella Immunopharma: Price-to-Projected Revenue Ratio

Estrella Immunopharma (ESLA) develops innovative T-cells that extend patient life and suppress relapses. The forward P/S trajectory on the GURU.Markets chart shows that the current level is . The ARTEMIS platform for combating lymphomas ensures strong pricing power. Meanwhile, the company adheres to environmental standards by controlling chemical disposal within its laboratories.

ESLA (Estrella Immunopharma, Inc.) Price to Expected Revenue Ratio history from 07/04/2022 to 11/15/2026

ESLA (estrellabio.com): analytical breakdowns and indicator data

- current price and projected stock value:

Stock Price estrellabio.com|ESLA - Average Forecast Price

- company stock capitalization data:

Market Value Estrella Bio|ESLA - Company Buyout Price

- book value of equity indicators:

Accounting Value per Share Estrella Immunopharma|ESLA - Total Net Assets|Market Value to Book Value Ratio estrellabio.com|ESLA - Aggregate Asset Value

- company liabilities and liquidity data:

Total Debt to Capital Estrella Immunopharma|ESLA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Estrella Immunopharma, Inc.|ESLA - Company Debts|Debt to Book Capitalization Ratio Estrella Immunopharma, Inc.|ESLA - Company Long-Term Debt|Company Short-Term Debts Estrella Immunopharma|Quick Liquidity Indicator estrellabio.com

- net income and valuation multiples indicators:

ESLA - Final Profit|Projected Future Earnings Estrella Immunopharma|ESLA - Business Payback Period|Future Price to Earnings estrellabio.com|ESLA - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Estrella Immunopharma Inc|ESLA - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Estrella Immunopharma|ESLA - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months estrellabio.com|ESLA - Earnings per share growth this year|Net earnings per share growth forecast for next year Estrella Immunopharma

- issuer revenue and sales details:

ESLA - Company Total Revenue|Company Projected Revenue Estrella Immunopharma, Inc.|ESLA - Price-to-Sales Ratio|Forward P/S Multiple Estrella Immunopharma Inc|ESLA - Revenue Dynamics YoY (Last Twelve Months)

Summary company analytics:ESLA (Estrella Bio)

The forward P/S is calculated as the ratio of current market capitalization to expected annual sales volume, reflecting market expectations regarding the value of each unit of future revenue. For Estrella Immunopharma (ESLA), this indicator assesses the investment attractiveness of the ARTEMIS platform in lymphoma therapy, allowing the forward price-to-sales multiple chart to track the valuation dynamics of the company's innovative potential between quarterly reports.

Who Estrella Immunopharma competes with

TG Therapeutics - Forward Price-to-Revenue Multiple|Forward P/S Multiple Arcellx Therapeutics ACLX|discmedicine.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio syndax.com|Kura Oncology (KURA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ADC Therapeutics Corp|FHTX (foghorntx.com) - Forward P/S Multiple|Price-to-Projected Revenue Ratio VOR|Forward Price-to-Revenue Multiple NKTX (Nkarta, Inc.)|Price to Expected Revenue Ratio COEP|Forward P/S Multiple ATNM (Actinium Pharma)|CASI (CASI Pharmaceuticals, Inc) - Future Price to Revenue|MRKR: Forward Price-to-Revenue Multiple|INAB - Forward P/S Multiple|ERNA (eternatx.com) - Forward Price-to-Revenue Multiple|GT Biopharma, Inc. - Forward Price to Sales|APTO (Aptose Biosciences) - Forward P/S Multiple|BPTH: Forward Price to Sales|Forward P/S Multiple MEIP|VINC (Vincerx Pharma) - Forward Price to Sales